Valuation: Annovis Bio, Inc.

Capitalization 56M 54.15M 50.92M 45.15M 80.18M 4.91B 89.41M 612M 227M 2.01B 210M 206M 8.47B P/E ratio 2024 *
-1.58x
P/E ratio 2025 * -1.58x
Enterprise value 51.2M 49.51M 46.55M 41.28M 73.31M 4.49B 81.74M 560M 208M 1.84B 192M 188M 7.74B EV / Sales 2024 *
-
EV / Sales 2025 * -
Free-Float
79.6%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-4.55%
1 week-39.63%
Current month-39.63%
1 month-43.02%
3 months-63.97%
6 months-64.36%
Current year-41.55%
More quotes
1 week
2.88
Extreme 2.88
4.48
1 month
2.88
Extreme 2.88
5.50
Current year
2.88
Extreme 2.88
5.60
1 year
2.88
Extreme 2.88
20.00
3 years
2.88
Extreme 2.88
23.91
5 years
2.42
Extreme 2.418
132.00
10 years
2.42
Extreme 2.418
132.00
More quotes
Director TitleAgeSince
Chief Executive Officer 74 2008-04-30
Director of Finance/CFO 62 2024-12-03
Chief Tech/Sci/R&D Officer - -
Manager TitleAgeSince
Director/Board Member 74 2008-04-30
Chairman 74 2015-01-06
Director/Board Member 69 2014-12-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-4.55%-39.63%-72.88%-80.00% 56M
-2.46%+1.65%+10.93%+94.79% 121B
-1.67%+5.50%-24.98%+14.90% 75.99B
-0.94%-1.71%+74.01%+155.04% 39.71B
-1.94%-4.98%+24.98%-26.31% 28.2B
-2.35%-0.66%+56.42%+5.83% 23.85B
+0.21%+5.08%+9.51%-38.16% 22.87B
-2.71%-6.47%+381.10%+835.35% 14.83B
-1.03%+4.40%+179.84%+250.35% 14.3B
-18.53%-19.23%-8.78%+53.43% 12.41B
Average -3.60%-5.68%+63.02%+126.52% 35.31B
Weighted average by Cap. -2.42%+0.65%+36.08%+96.01%
See all sector performances

Financials

2024 *2025 *
Net sales - -
Net income -23.44M -22.67M -21.32M -18.9M -33.57M -2.06B -37.43M -256M -95.23M -843M -87.89M -86.11M -3.54B -37.3M -36.06M -33.91M -30.07M -53.4M -3.27B -59.55M -408M -152M -1.34B -140M -137M -5.64B
Net Debt -4.8M -4.64M -4.36M -3.87M -6.87M -421M -7.66M -52.48M -19.5M -173M -18M -17.63M -726M -15.3M -14.8M -13.91M -12.34M -21.91M -1.34B -24.43M -167M -62.15M -550M -57.36M -56.2M -2.31B
More financial data * Estimated data
Logo Annovis Bio, Inc.
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.
Employees
11
More about the company
Date Price Change Volume
25-02-07 2.940 $ -4.55% 739,636
25-02-06 3.080 $ -1.91% 833,438
25-02-05 3.140 $ 0.00% 911,369
25-02-04 3.140 $ -3.09% 1,385,680
25-02-03 3.240 $ -33.47% 3,753,913

Delayed Quote Nyse, February 07, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.940USD
Average target price
34.80USD
Spread / Average Target
+1,083.67%
Consensus

Quarterly revenue - Rate of surprise